OncoMap

Who We Are

OncoMap is at the forefront of precision oncology, leveraging cutting-edge machine learning and transcriptomic analysis to revolutionize head and neck cancer treatment decision-making. In today's world, immunotherapy, specifically PD-1 inhibitors, has emerged as a transformative treatment option for head and neck cancer patients. However, the challenge lies in identifying which patients will truly benefit from this therapy, as head and neck cancer lies at one of the lowest response rates of 15-30%. Due to this, many clinicians administer the therapy, which costs over $150,000, without knowing if it would help the patient. OncoMap addresses this critical need by developing advanced predictive models that analyze tumor transcriptomic data to accurately forecast patient responses to immunotherapy while also predicting specific oncogenic features.

OncoMap's team consists of 2 research interns, Anshul R. and Krishay S., from the Holland Lab at Fred Hutchinson Cancer Research Center in Bellevue, Washington. OncoMap's team works together to translate complex genomic data into actionable clinical insights, empowering oncologists and pathologists to make informed treatment decisions tailored to each patient's unique tumor profile.

OncoMap strives for hyper-personalization; every head and neck cancer patient deserves a treatment plan as unique as their profile.